Search

Your search keyword '"Imanol Otaegui Irurueta"' showing total 9 results
Start Over Author "Imanol Otaegui Irurueta"
9 results on '"Imanol Otaegui Irurueta"'

1. Estudio observacional prospectivo EPIC03-BIOSS. Análisis del stent dedicado BIOSS LIM C en angioplastias en bifurcación

Author

Bruno García del Blanco, Josep Gómez Lara, Juan Carlos Rama Merchán, Luis Renier Goncalves-Ramírez, Imanol Otaegui Irurueta, Eduard Bosch Peligero, Julio Carballo Garrido, Jorge Palazuelos Molinero, Juan Antonio Bullones Ramírez, Joan Casanova Sandoval, José Ramón Rumoroso Cuevas, Germán Calle Pérez, Eduard Fernández Nofrerías, María Ángeles Carmona Ramírez, and Armando Pérez de Prado

Subjects
Stent dedicado, Lesión en bifurcación, Stent liberador de sirolimus BIOSS LIM C, Internal medicine, RC31-1245
Abstract

RESUMEN Introducción y objetivos: El estudio EPIC03-BIOSS se llevó a cabo para describir la eficacia del stent farmacoactivo dedicado BIOSS LIM C en el tratamiento de las lesiones en bifurcación, así como la modificación inducida sobre la lesión en bifurcación por angiografía cuantitativa automatizada. Métodos: Estudio observacional prospectivo en el que se incluyeron 124 pacientes con lesión en bifurcación tratados con stent farmacoactivo BIOSS LIM C, excluidas las lesiones por reestenosis y aquellas en las que no había afección del vaso principal. Resultados: El stent se implantó con éxito en 121 pacientes (97,6%); en 18 (14,5%) se utilizó una técnica de 2 stents. El análisis por angiografía cuantitativa automatizada mostró una estenosis residual media del 18% en el segmento proximal, de prácticamente el 0% en el segmento distal y del 21% en la rama lateral. Los resultados angiográficos para la técnica de doble stent muestran unos diámetros (2,12 ± 0,30 frente a 1,60 ± 0,42 mm; p < 0,001) y estenosis residuales (18,36 ± 9,94 frente a 28,49 ± 14,19%; p < 0,01) significativamente mejores. La distorsión sobre la angulación nativa del vaso resultó mínima, con una reducción absoluta de unos 5° (52,8 ± 18,4 frente a 47,5 ± 17,2°; p = 0,001). Conclusiones: El stent BIOSS LIM C consigue una elevada tasa de éxito para el tratamiento de las lesiones en bifurcación. Los resultados angiográficos son buenos, destacando la escasa distorsión sobre la angulación nativa del vaso y los excelentes resultados angiográficos de la técnica de doble stent. Consideramos que puede ser un buen dispositivo para el tratamiento de las bifurcaciones, con la ventaja de poder facilitar la implantación no prevista de un segundo stent.

Published
2022
Full Text
View/download PDF

2. EPIC03-BIOSS observational prospective study. Performance analysis of the BIOSS LIM C dedicated stent in coronary bifurcation lesion angioplasty

Author

Bruno García del Blanco, Josep Gómez Lara, Juan Carlos Rama Merchán, Luis Renier Goncalves-Ramírez, Imanol Otaegui Irurueta, Eduard Bosch Peligero, Julio Carballo Garrido, Jorge Palazuelos Molinero, Juan Antonio Bullones Ramírez, Joan Casanova Sandoval, José Ramón Rumoroso Cuevas, Germán Calle Pérez, Eduard Fernández Nofrerías, María Ángeles Carmona Ramírez, and Armando Pérez de Prado

Subjects
Dedicated stent, Bifurcation lesion, BIOSS LIM C sirolimus-eluting stent, Medicine
Abstract

Abstract Introduction and objectives: To describe the efficacy of the BIOSS LIM C dedicated sirolimus-eluting stent to treat coronary bifurcation lesions, and impact on the bifurcation angle and carina through quantitative coronary angiography. Methods: Observational prospective study including 124 patients with bifurcation lesions treated with a BIOSS LIM C dedicated sirolimus-eluting stent excluding restenotic lesions and those without main vessel involvement. Results: The stent was successfully deployed in 121 patients (97.6%) while in 18 (14.5%) double stenting was used. The quantitative coronary analysis has shown proper stent expansion with a mean residual stenosis of 18% in the proximal segment, nearly 0% in the distal segment, and 21% in the side branch. The angiographic results of double stenting showed higher mean diameters (2.12 ± 0.30 vs 1.60 ± 0.42; P < .001), and lower residual stenosis (18.36 ± 9.94 vs 28.49 ± 14.19%, P < .01). Distortion imposed on the bifurcation angulation was minimal with an absolute reduction of 5 degrees (52.8 ± 18.4 vs 47.5 ± 17.2; P = .001). Conclusions: The dedicated BIOSS LIM C stent has had a very high success rate to treat coronary bifurcation lesions. Angiographic results are good with a remarkably low impact on the native bifurcation angulation, and excellent results from double stenting. We think this can be a very useful device to treat coronary bifurcation lesions with the advantage of easing out the bailout deployment of a second stent into the side branch.

Published
2022
Full Text
View/download PDF

3. Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes.

Author

Florian Krackhardt, Matthias Waliszewski, Wan Azman Wan Ahmad, Viktor Kočka, Petr Toušek, Bronislav Janek, Milan Trenčan, Peter Krajči, Fernando Lozano, Koldobika Garcia-San Roman, Imanol Otaegui Irurueta, Bruno Garcia Del Blanco, Lucie Wachowiak, Victoria Vilalta Del Olmo, Eduard Fernandez Nofrerías, Myung Ho Jeong, Byung-Chun Jung, Kyu-Rock Han, Christophe Piot, Laurent Sebagh, Jérôme Rischner, Michel Pansieri, Matthias Leschke, and Tae Hoon Ahn

Subjects
Medicine, Science
Abstract

BackgroundThe objective of this study was to assess regional and ethnic differences in an unselected patient population treated with polymer-free sirolimus-eluting stents (PF-SES) in Asia and Europe.MethodsTwo all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined for data analysis to assure sufficient statistical power. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 9-12 months.ResultsOf the total population of 7243 patients, 44.0% (3186) were recruited in the Mediterranean region and 32.0% (2317) in central Europe. The most prominent Asian region was South Korea (17.6%, 1274) followed by Malaysia (5.7%, 413). Major cardiovascular risk factors varied significantly across regions. The overall rates for accumulated TLR and MACE were low with 2.2% (140/6374) and 4.4% (279/6374), respectively. In ACS patients, there were no differences in terms of MACE, TLR, MI and accumulated mortality between the investigated regions. Moreover, dual antiplatelet therapy (DAPT) regimens were substantially longer in Asian countries even in patients with stable coronary artery disease as compared to those in Europe.ConclusionsPF-SES angioplasty is associated with low clinical event rates in all regions. Further reductions in clinical event rates seem to be associated with longer DAPT regimens.

Published
2020
Full Text
View/download PDF

4. Can an ultrathin strut stent design and a polymer free, proendothelializing probucol matrix coating improve early strut healing? The FRIENDLY-OCT trial. An intra-patient randomized study with OCT, evaluating early strut coverage of a novel probucol coated polymer-free and ultra-thin strut sirolimus-eluting stent compared to a biodegradable polymer sirolimus-eluting stent

Author

Imanol Otaegui Irurueta, Silvia González Sucarrats, Jose Luis Barrón Molina, Armando Pérez de Prado, Monica Massotti, Maria Ángeles Carmona Ramírez, Gerard Martí, Neus Bellera, Bernat Serra, Vicenç Serra, Enric Domingo, María López-Benito, Manuel Sabaté, Ignacio Ferreira González, and Bruno García del Blanco

Subjects
Sirolimus, Percutaneous Coronary Intervention, Probucol, Treatment Outcome, Polymers, Absorbable Implants, Humans, Drug-Eluting Stents, Stents, Cardiology and Cardiovascular Medicine, Prosthesis Design, Tomography, Optical Coherence
Abstract

incomplete strut coverage determines the risk of stent thrombosis in the first months after stent implantation.To evaluate the potential better early healing of a novel probucol coated polymer free ultra-thin strut sirolimus eluting stent (PF-SES). [Clinical trial unique identifier: NCT02785237].Patients with two (angiographically similar) lesions with clinical indication for PCI were enrolled. The investigated stent was compared to a thin strut, bioresorbable polymer, sirolimus eluting stent (BP-SES). Every patient received both stents, one in each lesion, assigned in a randomized sequence. OCT was systematically performed at 3 months. Primary end point was the difference in the proportion of covered struts at 3 months (defined as ≥20 μm of tissue coverage). Secondary end points included differences in percentage of uncovered struts (0 μm coverage), mean strut coverage thickness, and malapposed struts' coverage proportion. Major adverse cardiac events (cardiac death, myocardial infarction, target lesion revascularization, and definite or probable stent thrombosis) at 12 months were also evaluated.70 patients were included. At 3 months, a consistent and significantly higher strut coverage rate (≥20 μm) was observed in PF-SES as compared to BP-SES, both for well apposed (87.3% versus 79.1%, p 0.001) and malapposed struts (50.4% vs 37.8%, p 0.00). Uncoverage rate (0 μm) was also significantly lower for the PF-SES (3.1% vs 5.3%, p 0.001). There were no differences in clinical endpoints.The probucol coated non-polymeric ultra-thin strut sirolimus eluting stent showed a significantly better early strut coverage at 3 months.

Published
2021

7. Ultrashort 1- to 3-month double antiplatelet therapy after drug-eluting stent implantation or the conquest of the South Pole

Author

Imanol Otaegui Irurueta, Gerard Martí Aguasca, and Bruno García del Blanco

Subjects
medicine.medical_specialty, Ticlopidine, business.industry, medicine.medical_treatment, MEDLINE, Drug-Eluting Stents, General Medicine, Surgery, CONQUEST, Clopidogrel, Treatment Outcome, Drug-eluting stent, medicine, Humans, Drug Therapy, Combination, business, Platelet Aggregation Inhibitors
Published
2020

8. Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes

Author

Myung Ho Jeong, Christophe Piot, Jérôme Rischner, Fernando Lozano, Tae Hoon Ahn, Bruno García del Blanco, Victoria Vilalta del Olmo, Byung-Chun Jung, Peter Krajči, Petr Tousek, Matthias Waliszewski, Lucie Wachowiak, Koldobika Garcia-San Roman, Michel Pansieri, Matthias Leschke, Eduard Fernandez Nofrerias, Kyu-Rock Han, Wan Azman Wan Ahmad, Milan Trenčan, Laurent Sebagh, Bronislav Janek, Viktor Kočka, Imanol Otaegui Irurueta, Florian Krackhardt, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], B. Braun Melsungen AG, University of Malaya [Kuala Lumpur, Malaisie], University Hospital Kralovské Vinohrady, Institute for Clinical and Experimental Medicine (IKEM), Matej Bel University (UMB), Hospital General de Ciudad Real (HGUCR), University of Castilla-La Mancha (UCLM), Hospital Universitario Cruces = Cruces University Hospital, Vall d'Hebron University Hospital [Barcelona], B. Braun Medical (Saint-Cloud), Hospital Universitario Germans Trias I Pujol, Chonnam National University [Gwangju], Daegu Fatima Hospital, Kangdong Sacred Heart Hospital, Hallym University, Clinique du Millénaire - Oc Santé [Montpellier], Oc Santé [Montpellier], Clinique Turin, Hôpital Albert Schweitzer, Centre Hospitalier Henri Duffaut (Avignon), Städtische Kliniken, and Gachon University Gil Medical Center [Incheon, Republic of Korea]

Subjects
Male, Cardiovascular Procedures, Epidemiology, Polymers, medicine.medical_treatment, Myocardial Infarction, Coronary Artery Disease, 030204 cardiovascular system & hematology, Pathology and Laboratory Medicine, Antiplatelet Therapy, Geographical Locations, Coronary artery disease, Endocrinology, 0302 clinical medicine, MESH: Mediterranean Region, Medicine and Health Sciences, Ethnicity, Clinical endpoint, Prospective Studies, 030212 general & internal medicine, MESH: Coronary Artery Disease, MESH: Incidence, Prospective cohort study, MESH: Aged, Multidisciplinary, MESH: Middle Aged, Pharmaceutics, Mediterranean Region, Incidence, Incidence (epidemiology), Drug-Eluting Stents, MESH: Follow-Up Studies, Middle Aged, Prognosis, 3. Good health, MESH: Polymers, Europe, MESH: Malaysia, MESH: Myocardial Infarction, Medicine, Female, MESH: Ethnic Groups, MESH: Immunosuppressive Agents, MESH: Percutaneous Coronary Intervention, Immunosuppressive Agents, Research Article, MESH: Drug-Eluting Stents, MESH: Republic of Korea, medicine.medical_specialty, Asia, Coronary Stenting, Endocrine Disorders, Science, Surgical and Invasive Medical Procedures, MESH: Prognosis, Ethnic Epidemiology, 03 medical and health sciences, Signs and Symptoms, Percutaneous Coronary Intervention, Drug Therapy, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diagnostic Medicine, South Korea, Internal medicine, Angioplasty, Republic of Korea, Diabetes Mellitus, medicine, Humans, Aged, Sirolimus, MESH: Humans, business.industry, Malaysia, Stent, medicine.disease, MESH: Male, MESH: Prospective Studies, Metabolic Disorders, People and Places, Stent Implantation, Lesions, Observational study, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Sirolimus, MESH: Europe, business, MESH: Female, Mace, Follow-Up Studies
Abstract

Background The objective of this study was to assess regional and ethnic differences in an unselected patient population treated with polymer-free sirolimus-eluting stents (PF-SES) in Asia and Europe. Methods Two all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined for data analysis to assure sufficient statistical power. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 9-12 months. Results Of the total population of 7243 patients, 44.0% (3186) were recruited in the Mediterranean region and 32.0% (2317) in central Europe. The most prominent Asian region was South Korea (17.6%, 1274) followed by Malaysia (5.7%, 413). Major cardiovascular risk factors varied significantly across regions. The overall rates for accumulated TLR and MACE were low with 2.2% (140/6374) and 4.4% (279/6374), respectively. In ACS patients, there were no differences in terms of MACE, TLR, MI and accumulated mortality between the investigated regions. Moreover, dual antiplatelet therapy (DAPT) regimens were substantially longer in Asian countries even in patients with stable coronary artery disease as compared to those in Europe. Conclusions PF-SES angioplasty is associated with low clinical event rates in all regions. Further reductions in clinical event rates seem to be associated with longer DAPT regimens.

Published
2020

9. CT or Invasive Coronary Angiography in Stable Chest Pain

Author

Pál Maurovich-Horvat, 1, Maria Bosserdt, 1, F Kofoed, Klaus, Nina Rieckmann, 1, Theodora Benedek, 1, Patrick Donnelly, 1, José Rodriguez-Palomares, 1, Andrejs Erglis, 1, Cyril Štěchovský, 1, Gintare Šakalyte, 1, Nada Čemerlić Adić, 1, Matthias Gutberlet, 1, D Dodd, Jonathan, Ignacio Diez, 1, Gershan Davis, 1, Elke Zimmermann, 1, Cezary Kępka, 1, Radosav Vidakovic, 1, Marco Francone, 1, Małgorzata Ilnicka-Suckiel, 1, Fabian Plank, 1, Juhani Knuuti, 1, Rita Faria, 1, Stephen Schröder, 1, Colin Berry, 1, Luca Saba, 1, Balazs Ruzsics, 1, Christine Kubiak, 1, Iñaki Gutierrez-Ibarluzea, 1, Kristian Schultz Hansen, 1, Jacqueline Müller-Nordhorn, 1, Bela Merkely, 1, D Knudsen, Andreas, Imre Benedek, 1, Clare Orr, 1, Filipa Xavier Valente, 1, Ligita Zvaigzne, 1, Vojtěch Suchánek, 1, Laura Zajančkauskiene, 1, Filip Adić, 1, Michael Woinke, 1, Mark Hensey, 1, Iñigo Lecumberri, 1, Erica Thwaite, 1, Michael Laule, 1, Mariusz Kruk, 1, N Neskovic, Aleksandar, Massimo Mancone, 1, Donata Kuśmierz, 1, Gudrun Feuchtner, 1, Mikko Pietilä, 1, Vasco Gama Ribeiro, 1, Tanja Drosch, 1, Christian Delles, 1, Gildo Matta, 1, Michael Fisher, 1, Bálint Szilveszter, 1, Linnea Larsen, 1, Mihaela Ratiu, 1, Stephanie Kelly, 1, Bruno Garcia Del Blanco, 1, Ainhoa Rubio, 1, D Drobni, Zsófia, Birgit Jurlander, 1, Ioana Rodean, 1, Susan Regan, 1, Hug Cuéllar Calabria, 1, Melinda Boussoussou, 1, Thomas Engstrøm, 1, Roxana Hodas, 1, E Napp, Adriane, Robert Haase, 1, Sarah Feger, 1, M Serna-Higuita, Lina, Konrad Neumann, 1, Henryk Dreger, 1, Matthias Rief, 1, Viktoria Wieske, 1, Melanie Estrella, 1, Peter Martus, 1, Marc, Dewey, Béla, Merkely, Pál, Maurovich-Horvat, Thomas, Engstroem, Klaus, F. Kofoed, Imre, Benedek, Theodora, Benedek, Patrick, Donnelly, José, F. Rodríguez-Palomares, Bruno Garcia Del Blanco, Andrejs, Erglis, Ligita, Zvaigzne, Vojtěch, Suchánek, Josef, Veselka, Antanas, Jankauskas, Gintare, Šakalyte, Nada Čemerlić Ađić, Oto, Ađić, Matthias, Gutberlet, Michael, Woinke, Jonathan, D. Dodd, Martin, Quinn, Ignacio Díez González, Inigo, Lecumberri, Gershan, K. Davis, Erika, Thwaite, Michael, Laule, Elke, Zimmermann, Henryk, Dreger, Matthias, Rief, Cezary, Kępka, Mariusz, Kruk, Aleksandar, N. Neskovic, Radosav, Vidakovic, Marco Francone, Massimo Mancone, Tomasz, Haran, Malgorzata, Ilnicka-Suckiel, Gudrun, Feuchtner, Guy, Friedrich, Juhani, Knuuti, Mikko, Pietilä, Rita, Faria, Vasco Gama Ribeiro, Stephen, Schröder, Thomas, Zelesny, Christian, Delles, Colin, Berry, Bruno, Loi, Gildo, Matta, Michael, Fisher, Balasz, Ruzsics, Adriane, E. Napp, Maria, Bosserdt, Melanie, Estrella, Jacob, Geleijns, Christine, Kubiak, Corinna, Meier-Windhorst, Rita, Pilger, Iñaki, Gutiérrez-Ibarluzea, Nora, Ibargoyen-Roteta, Itziar, Etxeandia, Gaizka, Benguria-Arrate, Lorea, Galnares-Cordero, Karsten, Vrangbaeck, Hans, Keiding, Kristian Schultz Hansen, Jacqueline, Müller-Nordhorn, Nina, Rieckmann, Peter, Schlattmann, Mihály, Károlyi, Júlia, Karády, Laszló, Gellér, Levente, Molnár, Tamás, Bárány, István, Édes, Dávid, Becker, Száraz Lili Milan Vecsey-Nagy, Borbala, Vattay, Tem, Jørgensen, Knut, Lindvig, Charlotte, Sørum, Helena Domínguez Vall-Lamora, Thomas, Hermann, Charlotte, Kragelund, Thomas Fritz Hansen, Jawdat, Abdulla, Jens Dahlgaard Hove, Kjeld Skødebjerg Kristensen, Leah, Hammond, Albert Roque Pérez, Imanol Otaegui Irurueta, Enzo Javier Alderete, Sebastian, Albornoz, Karlis, Strenge, Marina, Berzina, Iveta, Mintale, Marija, Tokmanceva, Linda, Glazere, Vita, Saripo, Zanda, Krastina, Dace, Sondore, Theodor, Adla, Martin, Horváth, Tadeáš, Butta, Petra, Hajžmanová, Audronė, Vaitiekienė, Gediminas, Jaruševičius, Kristina, Morkūnaitė, Eglė, Montrimavičienė, Laura, Radionovaitė, Milenko, Cankovic, Andrea, Ljubotina, Christian, Krieghoff, Robin, Gohman, Fabian, Juhrich, Patrick, Seitz, Stephen, Keane, Diarmaid, Cadogan, Claire, O. Dowling, Rudaynah, A. Alali, Siobhan, Quinlan, Edel, Meaney, Peter, Doran, Gerald, Kearns, Siobhan, O. Rourke, Sarah, Foley, Joanne, Clarke, Abdi, Abdi, Aine, Hahessy, Brian, Meehan, Michelle, Healy, Sonya, Allen, Colin, P. Cantwell, Niall, Mulvihill, Charles, Mccreery, David, Keane, Ken, Mcdonald, Peter, Quigley, Sadhbh, O. Sullivan, Brian, O. Riordan, Lara, Toerien, John, Irwin, Paddy, Barrett, Dermot, Malone, Abel, Andres, Eva, Amuriza, Arun, Ranjit, Jaroslav, Hasara, Mohammed, Obeidat, Catherine, Toohey, Sandra, Fullalove, Kate, Fenlon, Nicola, Lawler, Anju, Rawat, Francis, Beni, Julie, Ashcroft, Shirley, Cooper, Jeanette, Hawkins, Kate, Hughes, Nicola, Ashall, Doireann, Dickinson, Gemma, Halligan, Julie, Rawcliffe, Dominik, Laskowski, Anna-Maria, Mielke, Laura, Elzenbeck, Daniel, Preuß, Anne, Karas, Anja, Bärrn, Gustavo, Gehling, Florian, Specht, Lisa, Timm, Karl, Stangl, Verena, Stangl, Anna, Brand, Bernhard, Föllmer, Eser, Isler, Federico, Biavati, Mahmoud, Mohamed, Katrin, Stoyanova, Bohdan, Pryplotskyi, Christian, Wald, Steffen, Lukas, Anna, Oleksiak, Vladimir, Jovanovic, Aleksandra, Maksimovic, Milica, Stefanovic, Aleksandra, Zivanic, Andrea Ceccacci, Gianluca De Rubeis, Pambianchi, Giacomo, Paolo Severino, Tomasz, Harań, Natalia, Ilnicka, Katarzyna, Romanowska, Tomasz, Roleder, Christoph, Beyer, Antti, Saraste, Pedro, Teixeira, Mónica, Carvalho, Wilson, Ferreira, Claúdia, Dias, Nuno, Ferreira, Raquel Menezes Fernandes, André Azul Freitas, Pedro Ribeiro Queirós, Lisa Maria Costa Ribeiro Ferraz, Marion, Steindl, Giles, Roditi, Damien, Collison, Laura, Kelly, Katriona, Brooksbank, Andrew, Dougherty, Rosemary, Woodward, Elizabeth, Boyd, Kate, Smith, Michele, Porcu, Maurizio, Porcu, Francesco, Allegra, Vitanio, Palmisano, Stefano, Cossa, Alberto, Boi, Marco, Melis, Riccardo, Cau, and Christine, Denby

Subjects
Angina Pectoris Coronary Angiography Coronary Artery Disease Computed Tomography

Catalog

Books, media, physical & digital resources
See catalog results